These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885 [TBL] [Abstract][Full Text] [Related]
12. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283 [TBL] [Abstract][Full Text] [Related]
13. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441 [TBL] [Abstract][Full Text] [Related]
14. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma. Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837 [TBL] [Abstract][Full Text] [Related]
15. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Yeddula N; Xia Y; Ke E; Beumer J; Verma IM Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681 [TBL] [Abstract][Full Text] [Related]
16. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792 [TBL] [Abstract][Full Text] [Related]
17. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149 [TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Zhang J; Park D; Shin DM; Deng X Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706 [TBL] [Abstract][Full Text] [Related]
20. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations. Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]